Business
Revolution Medicines, Inc.: We use these mediums, including our website, to communicate with our stockholders and the public about our company, our products and other issues.
Revenue was $0, while Net income decreased 88.5% to ($1.13B).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $0Watch
- Profitability — Net income ($1.13B)Watch
- Cash generation — Free cash flow ($913.7M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 42 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Revolution Medicines, Inc.'s own filings, the day they're filed.
- Eric T. Schmidt · Directors · departureeff. 2023-09-05
- Lorence Kim · appointment
- Board's Research · director · departure
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-08-26
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Revolution Medicines, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.